Indrayani Biotech Ltd announced that in its Board meeting on April 3, 2025, it approved the issuance of partly paid-up equity shares by way of a rights issue for up to Rs 49.90 Crores, appointed Dhinakaran Rajagopal as CFO, and accepted Vinayaka Bodala's resignation effective the same day.